The Editorial on the Research Topic
The CXCR4 Ligand/Receptor Family and the DPP4 Protease in High-Risk Cardiovascular Patients
Cardiovascular disease (CVD) is the most common cause of morbidity and mortality worldwide and was responsible for 17.5 million deaths in 2012. This equals 31% of all deaths globally and is almost double the amount of cancer-related deaths (1). Although CVD encompasses a broad range of pathologic conditions, 80% of all CVD-related deaths are due to heart attacks and stroke (1). An important underlying pathology is atherosclerosis, a chronic inflammatory state of the arterial wall that is characterized by lipid deposition, dysfunction of the endothelium, and infiltration of inflammatory cells into the vessel wall, resulting in the development of atherosclerotic lesions (2).
Type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) have been identified as important risk factors for CVD. Fifty percent of patients with CKD stages 4–5 suffer from CVD (3), and cardiovascular mortality accounts for ~40–50% of all deaths in these patients, compared with 26% in controls with normal kidney function (4, 5). Also in patients with diabetes, CVD accounts for at least 50% of deaths (6). With currently around 10–13% of people presenting with CKD and more than 8% of adults suffering from diabetes (6–8), the social and economic burden of diabetes, CKD, and CVD is extremely high. Thus, a better understanding of the mechanisms contributing to and mediating the interplay between T2DM, CKD, and CVD is required to improve the prevention and treatment of these diseases.
In this Research Topic, we focus on the classical CXC chemokine receptor CXCR4 (9), its cognate ligand CXCL12 (10), and the chemokine-like cytokine macrophage migration inhibitory factor (MIF), which functions as a non-cognate ligand of CXCR4 (11), in the context of CVD. An emphasis is made on links with T2DM and CKD. Also, we discuss dipeptidyl peptidase-4 (DPP4) as an important protease known to destabilize CXCL12 and thus to influence signaling through the CXCL12/CXCR4 axis. Chemokines and their receptors are important mediators of cell mobilization, recruitment and arrest, and additionally more broadly induce cell activation by triggering various intracellular signaling tracks. Chemokines control basic homeostatic conditions but are also critically involved in inflammatory processes, e.g., in atherosclerosis (12, 13). Genome-wide association studies revealed single nucleotide polymorphisms connecting CXCL12 as well as MIF with CVD (2, 14–19), and a role for both of these mediators in T2DM and CKD has been reported. In this Research Topic, we introduce the reader to the comorbidities T2DM and CKD and their connection with CVD, and provide up-to-date information on the involvement of CXCL12/MIF/CXCR4 and DPP4 in each of these pathologies. One focus is laid upon providing insight on mechanistic level.
T2DM, CKD, and CVD: Comorbidities Interlinked on Mechanistic Level
There is clear-cut epidemiologic evidence linking the comorbidities T2DM and CKD with CVD. Progress has also been made to explain the comorbid status of these diseases on molecular level; however, the interaction seems highly complex and insight into the connecting mechanisms is mostly still in its infancy. Here, Schuett et al. (Germany) present an overview of the inflammatory processes underlying atherosclerosis and highlight the role of inflammation in T2DM and chronic inflammatory diseases in relation to CVD. The current prevalence and incidence of T2DM, CKD, and CVD are summarized by Gajjala et al. (Germany). They also provide insight into molecular mechanisms interconnecting these comorbidities.
Animal models allow us to investigate these interconnecting mechanisms in more detail and enable us to evaluate potential therapeutic strategies. Hewitson et al. (Australia) summarize available animal models for investigating mutual interactions between cardiac and renal injury and critically discuss how representative they are for human disease. This also includes an overview of animal models for hypertension, diabetes, and obesity, which are linked with kidney and cardiac injury through systemic alterations.
The CXCR4 Chemokine Receptor and Its Ligands CXCL12 and MIF: Molecular Aspects and Involvement in CVD, T2DM, and CKD
Pawig et al. (Germany) present the diversity and interconnections in the CXCR4 receptor/ligand family. Signaling pathways initiated by binding of CXCL12 vs. MIF to CXCR4 are discussed, and it is elaborated on how ACKR3 (previously called CXCR7) affects CXCR4 signaling. Finally, authors summarize the (patho)biological functions of CXCR4 signaling mediated by CXCL12 or MIF that are likely to be important in devising potential future therapies targeting this signaling axis.
van der Vorst et al. (Germany) present an overview of the role of CXCL12 vs. MIF in CVD, highlighting the differences and similarities. Vidakovic et al. (Serbia) discuss the controversial role of the CXCL12/CXCR4 axis in diabetes, whereas Morrison and Kleemann (The Netherlands) summarize the role of MIF in obesity, insulin resistance, T2DM, and associated hepatic comorbidities as revealed by both human and animal studies. Bruchfeld (Sweden) discusses MIF in the context of kidney disease, while complementarily, Valiño-Rivas et al. (Spain) elaborate on the expression and role of CD74, an additional receptor for MIF and the MIF homolog MIF-2 (or D-DT) in kidney injury.
DPP4 as Regulator of CXCL12 and Its Involvement in CVD, T2DM, and CKD
DPP4 (also known as CD26) is known to destabilize CXCL12. Therefore, our Research Topic also addresses molecular aspects and functions of this protease as well as its role in CVD, T2DM, and CKD. Waumans et al. (Belgium) provide a comprehensive insight into DPP4 and its role in the immune system and inflammatory diseases including atherosclerosis. This also includes an overview of other family members of the dipeptidyl peptidase family as well as of prolyl oligopeptidases and prolyl carboxypeptidases. Circulating DPP4 is increased in patients with T2DM, and DPP4 inhibition is used for treatment of T2DM. Thus, Röhrborn et al. (Germany) provide detailed insight into the expression, enzymatic activity, and function of DPP4 in the context of diabetes, based on in vitro, animal, and human studies. Also, mechanistic insight into the role of DPP4 in the T2DM-associated morbidities CVD and liver disease is provided. The role of DPP4 and its regulation of the CXCL12/CXCR4 axis in CVD are then discussed in more detail by Zhong and Rajagopalan (USA). Finally, Panchapakesan and Pollock (Australia) summarize potential renoprotective effects of DPP4 inhibitors in diabetic kidney disease and also discuss the cardiovascular safety profile of DPP4 inhibitors.
Altogether, this Research Topic aims to assist both specialists and interested non-specialists and to stimulate further initiatives to unravel the mechanistic involvement of the CXCR4 ligand/receptor family in the detrimental interplay between the comorbidities T2DM, CKD, and CVD, potentially paving the way for new therapeutic initiatives in the future.
Statements
Author contributions
All authors listed, have made substantial, direct and intellectual contribution to the work, and approved it for publication.
Acknowledgments
We thank all scientists who contributed to this Research Topic and EBook. This work was supported by the Interdisciplinary Centre for Clinical Research within the faculty of Medicine at the RWTH Aachen University (project K7-1) to JB and HN, by the Deutsche Forschungsgemeinschaft (DFG; grants SFB1123-A3, SFB-TRR57-P07) to JB, and within the framework of the Munich Cluster for Systems Neurology (EXC 1010 SyNergy) to JB.
Conflict of interest
The authors declare that this work was conducted in the absence of any commercial or financial relationships that could present a potential conflict of interest.
References
1
World Health Organization. Global Status Report on Noncommunicable Diseases. World Health Organization (2014).
2
WeberCNoelsH. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med (2011) 17:1410–22.10.1038/nm.2538
3
StevensPEO’donoghueDJDe LusignanSVan VlymenJKlebeBMiddletonRet alChronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int (2007) 72:92–9.10.1038/sj.ki.5002273
4
DreyNRoderickPMulleeMRogersonM. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis (2003) 42:677–84.10.1016/S0272-6386(03)00916-8
5
ThompsonSJamesMWiebeNHemmelgarnBMannsBKlarenbachSet alCause of death in patients with reduced kidney function. J Am Soc Nephrol (2015) 26(10):2504–11.10.1681/ASN.2014070714
6
International Diabetes Federation. IDF Diabetes Atlas. Sixth ed. International Diabetes Federation (2013). Available from: www.idf.org/diabetesatlas
7
East Midlands Public Health Observatory (EMPHO) and NHS Kidney Care. Kidney Disease: Key Facts and Figures. EMPHO, NHS Kidney Care (2010).
8
SaranRLiYRobinsonBAyanianJBalkrishnanRBragg-GreshamJet alUS renal data system 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis (2015) 65:A7.10.1053/j.ajkd.2015.05.001
9
WuBChienEYTMolCDFenaltiGLiuWKatritchVet alStructures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science (2010) 330:1066–71.10.1126/science.1194396
10
OberlinEAmaraABachelerieFBessiaCVirelizierJLArenzana-SeisdedosFet alThe CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature (1996) 382:833–5.10.1038/382833a0
11
BernhagenJKrohnRLueHGregoryJLZerneckeAKoenenRRet alMIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med (2007) 13:587–96.10.1038/nm1567
12
KoenenRRWeberC. Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov (2010) 9:141–53.10.1038/nrd3048
13
ZerneckeAWeberC. Chemokines in atherosclerosis: proceedings resumed. Arterioscler Thromb Vasc Biol (2014) 34:742–50.10.1161/ATVBAHA.113.301655
14
HerderCIlligTBaumertJMullerMKloppNKhuseyinovaNet alMacrophage migration inhibitory factor (MIF) and risk for coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Atherosclerosis (2008) 200:380–8.10.1016/j.atherosclerosis.2007.12.025
15
KathiresanSVoightBFPurcellSMusunuruKArdissinoDMannucciPMet alGenome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 41:334–41.10.1038/ng.327
16
TereshchenkoIPPetrkovaJMrazekFLuklJMaksimovVNRomaschenkoAGet alThe macrophage migration inhibitory factor (MIF) gene polymorphism in Czech and Russian patients with myocardial infarction. Clin Chim Acta (2009) 402:199–202.10.1016/j.cca.2008.12.034
17
SchunkertHErdmannJSamaniNJ. Genetics of myocardial infarction: a progress report. Eur Heart J (2010) 31:918–25.10.1093/eurheartj/ehq038
18
SchunkertHKonigIRKathiresanSReillyMPAssimesTLHolmHet alLarge-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 43:333–8.10.1038/ng.784
19
TillmannSBernhagenJNoelsH. Arrest functions of the MIF ligand/receptor axes in atherogenesis. Front Immunol (2013) 4:115.10.3389/fimmu.2013.00115
Summary
Keywords
cardiovascular diseases, diabetes mellitus, chronic kidney disease, CXCR4, CXCL12/SDF-1, MIF, CD26/DPP4, chemokine
Citation
Noels H and Bernhagen J (2016) Editorial: The CXCR4 Ligand/Receptor Family and the DPP4 Protease in High-Risk Cardiovascular Patients. Front. Immunol. 7:58. doi: 10.3389/fimmu.2016.00058
Received
21 January 2016
Accepted
05 February 2016
Published
19 February 2016
Volume
7 - 2016
Edited and reviewed by
Mario Mellado, Consejo Superior de Investigaciones Científicas, Spain
Updates
Copyright
© 2016 Noels and Bernhagen.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Heidi Noels, hnoels@ukaachen.de; Jürgen Bernhagen, juergen.bernhagen@med.uni-muenchen.de
Specialty section: This article was submitted to Chemoattractants, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.